How AI is supercharging drug development

Artificial intelligence is significantly accelerating drug development, reducing preclinical costs and timelines by up to 70%. This is driving demand for advanced software and computational tools, making computer screens as crucial as traditional labs in the drug design process. The aim is to increase the number of experimental treatments and improve the odds of clinical success, with a downstream impact on ‘wet labs’ for compound evaluation.

• AI is compressing preclinical costs and timelines in drug development by up to 70%.
• This is fueling demand for cutting-edge software, sequencing tools, and computer models.
• AI streamlines the R&D process before human testing begins, making computational tools vital.
• The goal is to generate more experimental treatments and increase the likelihood of clinical success.
• Demand for advanced software simulating biological processes and predicting drug interactions will rise.
• Companies are investing in ‘in silico’ platforms for virtual experiments and toxicity simulations.
• New drug development programs could grow by over 10% in three to five years, with potential for $1 billion in incremental spending.
• Skepticism exists regarding AI’s ability to factor in human responses and its impact on patient outcomes.
• China’s biotech advancements pose a competitive threat to U.S. research efforts.
  Continue reading https://www.axios.com/2026/07/20/artificial-intelligence-drug-development-impact